MAP2K7 and melanoma: BRAF and MEK inhibitors—the drugs vemurafenib (PLX4032; Zelboraf), a V600EBRAF inhibitor, and trametinib (GSK1120212; Mekinist), a MEK1/2 inhibitor, approved by FDA for the treatment of patients with advanced melanoma harboring mutation in BRAF (V600E) have been tested on six melanoma cell subpopulations.